Skip to content
Screener

Citius Oncology, Inc. CTOR Q3 2026 earnings

Reported August 14, 2026 · Before market open

Revenue$1.5MMiss by $1.0M
EPS-$0.08Miss by $0.01
Revenue estimate$2.5M
EPS estimate-$0.07

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$1.5M—
Gross profit$1.0M—
Operating income-$8.7M-76.3%
Net income-$8.9M-66.2%
EPS (diluted)-$0.080.0%

Balance sheet

See full
Cash & equivalents$16.6M+14,788,922%
Total debt$16.4M—
Total equity$40.4M+24.7%
Total assets$112.1M+22.2%

Cash flow

See full
Operating cash flow-$2.7M-97.4%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$83.24M-49.2%
Enterprise value$83.09M—

Returns & leverage

See full
Return on equity-126.6%+27.2pp
Debt / equity0.4×—
Current ratio0.7×+0.4×

FAQ

When did Citius Oncology, Inc. report Q3 2026 earnings?
Citius Oncology, Inc. (CTOR) reported Q3 2026 earnings on August 14, 2026 before market open.
What were Citius Oncology, Inc.'s Q3 2026 revenue and EPS?
Citius Oncology, Inc. reported revenue of $1.5M and eps of $-0.08 for Q3 2026.
Did Citius Oncology, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $2.5M by $1.0M. EPS missed the consensus estimate of $-0.07 by $0.01.
How did Citius Oncology, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 0.0% from $-0.08.
Where can I find Citius Oncology, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-088068) and the 10-Q periodic report (0001213900-26-090184) directly on SEC EDGAR. The filing index links above go to sec.gov.